Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Illumina heads into its October 30 earnings with a sharp divergence at its core: short sellers have been covering steadily for weeks, yet options traders turned their most defensive in a year on the very day the stock fell nearly 7%.
The short-selling picture is unambiguously improving. Short interest in Illumina has dropped 12.5% over the past week to 5.8% of the free float, a decline that has been building throughout September when shorts peaked near 10.8 million shares and have since shed roughly 1.9 million. The borrow market confirms there is little conviction left among remaining bears: the cost to borrow is a negligible 0.47%, down 17% over the past month, and availability is expansive at 657%, meaning there are nearly seven shares available to borrow for every one already shorted. The short score, which captures the full constellation of short-side pressure, has fallen from 52 in late September to 45 today, its lowest reading in the window. Shorts are not pressing this name.
Options traders told a different story on Tuesday. The put/call ratio closed at 0.67, its highest reading of the past year and nearly two standard deviations above its 20-day average of 0.54. That is a meaningful rotation into downside protection in a single session, and it coincided with the stock's 6.9% drop to $273.54. The setup is not a slow creep of defensiveness; the PCR was running in the mid-0.50s for most of September and jumped sharply this week. Whether that reflects hedges into earnings or reaction to the day's move itself, it marks the most charged options day Illumina has seen in at least a year.
The Street has been aggressively upgrading its view, though a notable outlier persists. Four firms raised targets in the past ten days alone, with RBC Capital lifting to $310, Guggenheim to $305, Leerink Partners to $300, and Piper Sandler to $305, all maintaining positive ratings. UBS upgraded from Neutral to Buy in early September, pushing its target from $135 to $260. Against that backdrop, Barclays reiterated Underweight on Tuesday and raised its target only to $200, still a full 27% below the current price. The consensus mean target of $229 now sits well below the stock's $273 close, suggesting the consensus math has not fully caught up with the pace of recent upgrades, or that the holdout bears at Barclays and Citi (target $113) carry enough weight to drag the average down. The bull case rests on clinical sequencing growth running at 20% year-on-year ex-China and a durable moat in oncology testing. The bear case focuses on per-sample price deflation, weak academic and pharma spending, and China exposure still representing around 5% of 2026 revenue, down from 10% a few years ago.
One insider activity thread is worth flagging. Director Keith Meister sold more than 132,000 shares across three sessions in early September at prices around $217 to $219, generating roughly $26 million in proceeds. Those sales were not declared under a pre-arranged 10b5-1 plan. The stock has since rallied more than 25% from those levels. The same director received a minor grant of 107 shares on September 30 at the same price, a routine equity award that does not offset the significance of the prior sales. FMR filed a fresh Schedule 13G today disclosing a 10.7% stake, while Capital World Investors trimmed from 13.2% to 10.3% in a May amendment, suggesting some rotation among the larger holders.
The last earnings print, in late July, produced a 5.3% one-day gain, though the five-day return faded back to flat. With 23 days to the October 30 report, the week's combination of short covering, a target-price upgrade wave from bulls, a persistent Barclays bear call, and the sharpest options defensiveness in a year makes the character of the next print the key variable to watch.
See the live data behind this article on ORTEX.
Open ILMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
